INFO & CONTACTS:  +39 02 2390 1

A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination with Standard of Care Agents in HLA-A*02:01 Positive Participants with Advanced PRAME Positive Cancers

Phase: Phase I clinical trials

Principal Investigator: Dott. Di Nicola Massimo

Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)

Drug: IMC-P115C, Bevacizumab, Olaparib, pembrolizumab/carboplatin/paclitaxel/pemetrexed, ipilimumab/nivolumab

Pathologies: Advanced Solid Tumours

ClinicalTrials.gov: Read the details about clinical trials

Phase 1, multicenter, open-label, first-in-human study of IMC-P115C in HLA-A*02:01-positive participants with advanced cancers that are PRAME-positive. PRAME is a cancer testis antigen (CTA) that is frequently highly expressed in a range of solid and hematologic malignancies

This study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and antitumor activity of IMC-P115C as monotherapy and in combination with other therapies. 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe